• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Michaelis-Menten kinetics of stiripentol in normal humans.

作者信息

Levy R H, Loiseau P, Guyot M, Blehaut H M, Tor J, Moreland T A

出版信息

Epilepsia. 1984 Aug;25(4):486-91. doi: 10.1111/j.1528-1157.1984.tb03448.x.

DOI:10.1111/j.1528-1157.1984.tb03448.x
PMID:6745219
Abstract

Michaelis-Menten kinetic parameters for stiripentol, and anticonvulsant, were assessed in six normal volunteers. Stiripentol was administered orally three times a day in dosage increments of 600, 1,200, and 1,800 mg/day for consecutive periods of 3, 4, and 7 days, respectively. Stiripentol steady-state levels at the three dosing rates increased more than proportionally with dose. The mean +/- SD oral clearance of stiripentol at 600 mg/day (1,090 +/- 624 L/day) was significantly greater (p less than 0.01) than at 1,200 (506 +/- 219 L/day) or 1,800 (405 +/- 151 L/day) mg/day. Average steady-state concentrations predicted from individually determined Vm and Km parameters were in good agreement with experimentally observed levels, indicating that the kinetics of stiripentol are of the Michaelis-Menten type. The mean Vm, Km, and Vm/Km ratio were 2,299 +/- 490 mg/day, 2.20 +/- 1.28 mg/L, and 1,241 +/- 837 L/day, respectively. Neuropsychological tests carried out before and after 14 days of stiripentol treatment showed a significant decline in verbal learning ability (p = 0.038) and a significant improvement in a test of memory and attention (p less than 0.01).

摘要

相似文献

1
Michaelis-Menten kinetics of stiripentol in normal humans.
Epilepsia. 1984 Aug;25(4):486-91. doi: 10.1111/j.1528-1157.1984.tb03448.x.
2
Stiripentol kinetics in epilepsy: nonlinearity and interactions.癫痫中司替戊醇的动力学:非线性与相互作用。
Clin Pharmacol Ther. 1984 Nov;36(5):661-9. doi: 10.1038/clpt.1984.237.
3
Pharmacokinetics of stiripentol in normal man: evidence of nonlinearity.
J Clin Pharmacol. 1983 Nov-Dec;23(11-12):523-33. doi: 10.1002/j.1552-4604.1983.tb01799.x.
4
Pharmacokinetic profile of a new anticonvulsant, stiripentol, in the rhesus monkey.
Epilepsia. 1983 Dec;24(6):692-703. doi: 10.1111/j.1528-1157.1983.tb04632.x.
5
A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study.
Arzneimittelforschung. 1984;34(2):199-204.
6
Comparative anticonvulsant potency and pharmacokinetics of (+)-and (-)-enantiomers of stiripentol.
Epilepsy Res. 1992 Jun;12(1):29-36. doi: 10.1016/0920-1211(92)90088-b.
7
Efficacy of stiripentol in the intravenous pentylenetetrazol infusion seizure model in the rat.
Epilepsy Res. 1990 Sep-Oct;7(1):40-8. doi: 10.1016/0920-1211(90)90052-w.
8
Reassessment of stiripentol pharmacokinetics in healthy adult volunteers.健康成年志愿者中司替戊醇药代动力学的再评估。
Epilepsy Res. 2014 Jul;108(5):909-16. doi: 10.1016/j.eplepsyres.2014.03.009. Epub 2014 Mar 26.
9
[Pharmacokinetic study of 3H-stiripentol in rats (author's transl)].
Eur J Drug Metab Pharmacokinet. 1982 Jan-Mar;7(1):5-10. doi: 10.1007/BF03189536.
10
[Pharmaco-cellular enzymology of the mode of action of Stiripentol during cardiazolic epilepsia--IV. Cellular and tissular repartition of 3H-Stiripentol (author's transl)].
Cell Mol Biol Incl Cyto Enzymol. 1979;24(1):51-60.

引用本文的文献

1
A Phase 1, Open-Label, Pharmacokinetic Trial to Investigate Possible Drug-Drug Interactions Between Clobazam, Stiripentol, or Valproate and Cannabidiol in Healthy Subjects.一项评估氯巴占、司替戊醇或丙戊酸与大麻二酚在健康受试者中是否存在药物相互作用的 1 期、开放性、药代动力学试验。
Clin Pharmacol Drug Dev. 2019 Nov;8(8):1009-1031. doi: 10.1002/cpdd.665. Epub 2019 Feb 21.
2
Audit of use of stiripentol in adults with Dravet syndrome.对患有德雷维特综合征的成人使用司替戊醇的审计。
Acta Neurol Scand. 2017 Jan;135(1):73-79. doi: 10.1111/ane.12611. Epub 2016 May 27.
3
A physiologically based pharmacokinetic model for clobazam and stiripentol in adults and children.
成人及儿童中氯巴占和司替戊醇的基于生理的药代动力学模型。
Pharm Res. 2015 Jan;32(1):144-57. doi: 10.1007/s11095-014-1451-y. Epub 2014 Jul 23.
4
Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.肝或肾功能损害患者的抗癫痫药物药代动力学。
Clin Pharmacokinet. 2014 Jan;53(1):29-49. doi: 10.1007/s40262-013-0107-0.
5
Stiripentol : in severe myoclonic epilepsy of infancy (dravet syndrome).司替戊醇:用于婴儿严重肌阵挛性癫痫(杜氏综合征)。
CNS Drugs. 2012 Nov;26(11):993-1001. doi: 10.1007/s40263-012-0004-3.
6
Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis.司替戊醇与卡马西平在小鼠最大电休克诱导癫痫模型中相互作用的双相特征:三维等效应线图分析
Naunyn Schmiedebergs Arch Pharmacol. 2006 Oct;374(1):51-64. doi: 10.1007/s00210-006-0100-3. Epub 2006 Sep 14.
7
The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramate, zonisamide and tiagabine.新型抗癫痫药物的临床药代动力学。重点关注托吡酯、唑尼沙胺和噻加宾。
Clin Pharmacokinet. 1996 Jul;31(1):29-46. doi: 10.2165/00003088-199631010-00003.
8
Comparative pharmacokinetics of the newer antiepileptic drugs.新型抗癫痫药物的比较药代动力学
Clin Pharmacokinet. 1993 Jun;24(6):441-52. doi: 10.2165/00003088-199324060-00002.
9
Newer antiepileptic drugs. Towards an improved risk-benefit ratio.新型抗癫痫药物。旨在改善风险效益比。
Drug Saf. 1994 Jul;11(1):37-67. doi: 10.2165/00002018-199411010-00005.
10
New anticonvulsant drugs. Focus on flunarizine, fosphenytoin, midazolam and stiripentol.新型抗惊厥药物。重点介绍氟桂利嗪、磷苯妥英、咪达唑仑和司替戊醇。
Drugs. 1994 Aug;48(2):153-71. doi: 10.2165/00003495-199448020-00003.